The US Food and Drug Administration (FDA) approved AstraZeneca’s cancer drugs Imfinzi and Imjudo in combination with chemotherapy to treat patients with stage 4 non-small cell lung cancer.
This approval is based on the phase 3 data published in September 2021. Imfinzi and Imjudo with chemotherapy have shown an overall 23 percent improvement in patients with stage 4 non-small cancer compared to patients who received chemotherapy.
AstraZeneca also noted that the availability of Soliris in China by the company’s rare disease focused group Alexion, a biopharmaceutical company based in Boston, which AstraZeneca purchased for 13.3 million dollars in July 2021.
Soliris is available in China for the treatment of atypical haemolytic uraemic syndrome and paroxysmal nocturnal haemoglobinuria in the adult patients. Atypical haemolytic uraemic syndrome mainly causes the development of abnormal blood clots in the small blood vessels in kindeys that can cause blockage in the blood flow. .
Marc Dunoyer, chief executive officer of Alexion, said that these achievements represent significant progress against their commitment to expand access to their rare disease medicines across the globe, including the introduction of innovative rare disease therapies in China.
